These studies have demonstrated the potential of NIS as sensitive reporter gene allowing spatial and temporal monitoring of NIS transgene expression following therapeutic radionuclide application in non-thyroid cancer settings. The gene discussed is SLC5A5; the disease is thyroid cancer.